• GW 6471: Reading PPARα Causality in Toxicology

  2026-09-27

  GW 6471 is a PPARα antagonist that can help researchers test whether receptor signaling contributes to an observed toxicological phenotype. This article examines how to interpret antagonist-based evidence, connect molecular changes to organism-level outcomes, and recognize the limits of translating zebrafish findings into other research models.

• Prochlorperazine: From D₂ Biology to Translation

  2026-09-26

  Prochlorperazine’s dopamine D₂ antagonism is only one part of a broader pharmacological profile. This translational perspective examines how to investigate its reported melanoma and antiviral effects, design experiments that account for polypharmacology, and interpret a rare but serious neurological safety signal without overextending the evidence.

• From WDR36 to Translational Control of Early Cell Fate

  2026-09-25

  A WDR36 study connects glycolytic metabolism with trophectoderm differentiation in human blastoid models. This article considers what that evidence means for translational study design, how to distinguish established findings from new hypotheses, and where a defined cytokine reagent may fit without conflating separate mechanisms.

• M344: A Cell-Permeable Histone Deacetylase Inhibitor

  2026-09-25

  M344 is a cell-permeable histone deacetylase inhibitor used to study histone acetylation, cell differentiation, and cancer-cell growth. Product information reports nanomolar enzyme inhibition and cellular effects, but assay conditions are not fully specified and the compound is a research tool rather than evidence of clinical efficacy.

• SETD7 Loss Promotes WAT Browning in Obese Mice

  2026-09-24

  The study identifies SETD7 as a negative regulator of thermogenic remodeling in inguinal white adipose tissue, linking its depletion to an Adcy7–Sirt1–CREB-associated program and improved metabolic outcomes in obese mice. Its combination of mouse, adipocyte, and transcriptomic evidence suggests a potential research direction for metabolic disorder research, while leaving human relevance and the precise molecular mechanism to be established.

• BMS-345541 (free base): Reliable Cell Assays

  2026-09-24

  A practical guide to using BMS-345541 (free base), SKU B4655, in viability, proliferation, and cytotoxicity workflows. Covers IKK/NF-κB rationale, solvent and dose planning, interpretation limits, and evidence-led product selection.

• RIPostC Limits Ferroptosis After Ischemic Stroke

  2026-09-23

  A 2024 study links remote ischemic postconditioning (RIPostC) to increased ketone-body production and reduced ferroptosis-related injury in rat stroke and neuronal cell models. Its findings connect energy metabolism, iron handling, and neuronal survival, while leaving open which individual ketone body is responsible and whether the mechanism translates to patients.

• Hollow CeO2 Nanoparticles for Colitis in Mice

  2026-09-23

  The reference study developed PEG-modified hollow cerium oxide nanoparticles that scavenge reactive oxygen species and reduce inflammatory signaling in a DSS-induced mouse model of colitis. Its central contribution is the combination of a hollow, uniform CeO2 architecture with PEG stabilization, linking material design to reduced cytokine production and MAPK pathway activity.

• Sorafenib: A Genotype-Aware Translational Playbook

  2026-09-22

  Sorafenib, also known as BAY-43-9006, is more than a broad kinase inhibitor. This thought-leadership guide connects its RAF, VEGFR, and PDGFR biology with ATRX-stratified glioma research, offering practical validation parameters and a disciplined framework for translating pathway inhibition into genotype-aware cancer biology.

• Bacteroides fragilis and Gut–Brain Antiseizure Signaling

  2026-09-22

  A 2026 Neuron study identifies a colonic ChAT+-vagal circuit through which Bacteroides fragilis suppresses seizures in mice and shows efficacy in children with refractory epilepsy. Its combination of microbiota manipulation, vagal recordings, causal neural perturbation, and clinical evaluation provides a mechanistic framework for microbiota-targeted antiseizure research.

• Bleomycin Sulfate: Reliable DNA Damage Models

  2026-09-21

  Learn how Bleomycin Sulfate, SKU A8331, supports controlled DNA-damage, cytotoxicity, and fibrosis workflows. This scenario-based guide connects mechanism, formulation, assay design, interpretation, and practical vendor-selection criteria for more defensible laboratory data.

• Reactive Astrocyte–Microglia Crosstalk in 1,2-DCE

  2026-09-21

  The reference study identifies reactive astrocytes as an early cellular driver of 2-chloroethanol-associated neuroinflammation, linking ROS-dependent p38 MAPK, NF-κB, and AP-1 signaling to A1 astrocyte activation and subsequent M1 microglial polarization. Its cell-based design provides a useful framework for separating direct chemical effects on microglia from cytokine-mediated astrocyte–microglia communication in toxic encephalopathy research.

• Azithromycin and Roxithromycin as Senolytics

  2026-09-20

  The reference study established a streamlined human fibroblast model for screening clinically approved drugs against senescent cells and identified azithromycin and roxithromycin as selective senolytic candidates. Its combination of viability, metabolic, autophagy, and real-time impedance measurements provides a useful framework for interpreting drug-induced senescent cell clearance while highlighting the need for orthogonal senescence validation.

• HyperScribe™ for Translational mRNA Design

  2026-09-19

  Explore how HyperScribe™ All in One mRNA Synthesis Kit II supports cap-, T7-, and poly(A)-focused mRNA workflows. This article translates findings from an LNP-mRNA fibroblast study into practical design, quality-control, and assay decisions for inflammatory disease research.

• Oteseconazole (VT-1161) Candida Workflows

  2026-09-18

  Build more reliable Candida susceptibility, resistance, and selectivity assays with Oteseconazole (VT-1161), a selective tetrazole CYP51 inhibitor. This practical workflow separates product-backed performance from assay starting points and shows how to troubleshoot solubility, controls, endpoint variation, and species-specific results.

8079 records 1/539 page Next 12345 下5页 Last page